Background: We compared the efficacy and safety of the low-molecular weight heparin enoxaparin with unfractionated heparin (UFH) for the prevention of venous thromboembolic disease in patients with heart failure or se...
详细信息
Background: We compared the efficacy and safety of the low-molecular weight heparin enoxaparin with unfractionated heparin (UFH) for the prevention of venous thromboembolic disease in patients with heart failure or severe respiratory disease. Methods: This was a multicenter, controlled, randomized, open study in which patients received either enoxaparin (40 mg once daily) or UFH (5000 IU 3 times daily) for 10 ± 2 days in 64 medical departments in Germany. Patients were stratified and enrolled according to their underlying disease: severe respiratory disease or heart failure. The primary efficacy parameter was a thromboembolic event up to 1 day after the treatment period. Results: Of the 665 patients enrolled, 451 patients were able to be evaluated in the primary efficacy analysis. The incidence of thromboembolic events was 8.4% with enoxaparin and 10.4% with UFH. Enoxaparin was at least as effective as UFH, with a 1-sided equivalence region of -4% (90% CI -2.5-6.5, P = .015). Enoxaparin was associated with fewer deaths, less bleeding, and significantly fewer adverse events (45.8% vs 53.8%, P = .044). Conclusions: Enoxaparin is at least as effective as UFH in the prevention of thromboembolic events in patients with heart failure or severe respiratory disease. Its beneficial safety profile and once-daily administration is advantageous for inpatient and outpatient use.
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel S. Hofer *E-mail: silviahofer@*** Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hofer S. Hunzik...
详细信息
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel S. Hofer *E-mail: silviahofer@*** Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hofer S. Hunziker Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hunziker L. Tornillo Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Tornillo C. U. Ludwig Search for other works by this author on: Oxford Academic PubMed Google Scholar C. U. Ludwig Annals of Oncology, Volume 14, Issue 2, 1 February 2003, Pages 340, https://***/10.1093/annonc/mdg052 Published: 01 February 2003
Primary treatment of Hodgkin’s disease G. P. Canellos Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar G...
详细信息
Primary treatment of Hodgkin’s disease G. P. Canellos Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar G. P. Canellos Annals of Oncology, Volume 13, Issue suppl_4, 1 October 2002, Pages 153–158, https://***/10.1093/annonc/mdf653 Published: 01 October 2002
Objective The purpose of the study was to establish a rebolus regimen for abciximab that restores pharmacologic glycoprotein (GP) IIb/IIIa receptor blockade within a short time frame (up to 48 hours) after completion ...
详细信息
Objective The purpose of the study was to establish a rebolus regimen for abciximab that restores pharmacologic glycoprotein (GP) IIb/IIIa receptor blockade within a short time frame (up to 48 hours) after completion of an initial treatment. Methods and Results The study was a single-center, nonrandomized, open-label dose escalation trial in healthy volunteers (n = 30). Each subject received a 0.25 mg/kg bolus and a 0.125 mug/kg per minute infusion of abciximab, followed by incremental bolus doses of the agent at 15-minute intervals up to 48 hours (10 per group) after completion of the infusion, (maximal cumulative rebolus dose of 0.25 mg/kg). Pharmacodynamic measurements (GP IIb/IIIa receptor blockade, turbidimetric and whole blood platelet aggregation with use of a rapid platelet function assay [RPFA]) were obtained at periodic intervals during and after administration of the abciximab bolus and infusion. At the time of the first rebolus, pharmacodynamic measurements were attained immediately before administration of each rebolus and 15 minutes after the last rebolus dose. In subjects who received reboluses 12 hours after infusion, a cumulative dose of 0.05 mg/kg restored >80% blockade of GP IIb/IIIa receptors and >80% inhibition of turbidimetric (5 and 20 mumol/L adenosine diphosphate) and RPFA aggregation in 10 of 10 subjects. At 24 hours after treatment, a cumulative abciximab bolus dose of 0.1 mg/kg restored >80% blockade of all 4 pharmacodynamic measurements in 10 of 10 subjects. At 48 hours after treatment, a cumulative bolus dose of 0.15 mg/kg restored >80% blockade of all 4 pharmacodynamic measurements in 10 of 10 subjects. Conclusions A fraction of the bolus of abciximab restored pharmacologic (>80%) GP IIb/IIIa receptor blockade when readministered at various postinfusion time points. These observations suggest that in the setting where acute readministration of abciximab is required less than a full bolus dose of the agent is warranted.
High-dose therapy in multiple myeloma J.-L. Harousseau Centre Hospitalier Universitaire, Service d’Hématologie, Nantes, France Search for other works by this author on: Oxford Academic PubMed Google Scholar J.-L...
详细信息
High-dose therapy in multiple myeloma J.-L. Harousseau Centre Hospitalier Universitaire, Service d’Hématologie, Nantes, France Search for other works by this author on: Oxford Academic PubMed Google Scholar J.-L. Harousseau Annals of Oncology, Volume 13, Issue suppl_4, 1 October 2002, Pages 49–54, https://***/10.1093/annonc/mdf638 Published: 01 October 2002
Methadone, a synthetic opioid agonist, is commonly used for the treatment of heroin dependence. Depending on how alcohol addiction is defined, rates of alcoholism vary among those attending methadone maintenance treat...
详细信息
Methadone, a synthetic opioid agonist, is commonly used for the treatment of heroin dependence. Depending on how alcohol addiction is defined, rates of alcoholism vary among those attending methadone maintenance treatment (MMT) programmes, Most of the current literature has shown that alcohol consumption increases during medium- or long-term MMT. However, up to now, no data have been reported on changes in alcohol intake among a population of heroin addicts with no alcohol-dependence diagnosis after short-term methadone administration, Thus, the aim of our study was to investigate alcohol consumption changes in a population of non-alcoholic heroin addict,during the first 4 weeks of a treatment programme (TP). The TP consisted of either MMT or non-methadone maintenance treatment (N-MMT) with a minimum duration of I year, A total of 359 heroin-addicted out-patients [274 males, (76.3%)], all of whom met DSM-IV criteria, were enrolled in the study, over a period of 4 months. Out of these 359 patients, 32 subjects (8.9%) dropped out, whereas 327 subjects (91.1%;249 males) continued the TP [105 (32.1%;78 males) in the MMT group and 222 (67.9%;171 males) in the N-MMT group]. A significant reduction in daily alcohol intake was observed in the MMT group, but not in the N-MMT group after the first 4 weeks of the TP. The results of the present study suggest a possible effect of short-term methadone administration in reducing alcohol consumption in a population of non-alcoholic heroin-addicted patients.
Background: The contribution of antibiotic prophylaxis to reduce surgical wound infection and endometritis after cesarean section is well-known. Despite the knowledge about the effectiveness of antibiotic prophylaxis ...
详细信息
Background: The contribution of antibiotic prophylaxis to reduce surgical wound infection and endometritis after cesarean section is well-known. Despite the knowledge about the effectiveness of antibiotic prophylaxis with this procedure, the administrative regimens are often inappropriate. Methods: The use of antibiotic prophylaxis in cesarean section was evaluated in a reference school hospital. Data were collected from medical records, and they correspond to the 9-month observation during 1995 and 1996. Results: The cesarean section rate was 26.4% in this period. The total procedures observed was 587. Antibiotic prophylaxis was prescribed in 358 procedures (61%). Cephalothin was the most prescribed drug (98.6%), with a regimen of 2 g intravenously after clamping of the umbilical cord and 2 more doses of 1g every 6 hours. Antibiotic prophylaxis was indicated more frequently in patients younger than 30 years and in those with rupture of membranes for more than 6 hours;such differences were significant (P < .05 and P < .00001, respectively). Conclusion: The prescribers met the hospital guidelines for antibiotic prophylaxis in only 37.1% of the cesarean sections performed.
Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase A. Vora Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute ...
详细信息
Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase A. Vora Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India *E-mail: manishabhutani@*** Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Vora M. Bhutani Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Bhutani A. Sharma Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Sharma V. Raina Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India Search for other works by this author on: Oxford Academic PubMed Google Scholar V. Raina Annals of Oncology, Volume 13, Issue 11, 1 November 2002, Pages 1833–1834, https://***/10.1093/annonc/mdf304 Published: 01 November 2002
暂无评论